AzTrials
AzTrials

HIVSHARENCT02050763

Assessing the Impact of an Intervention to Prevent Intimate Partner Violence and HIV in Uganda

A study testing The SHARE Project in people with HIV and Physical Abuse of Adult (If Focus of Attention is on Victim), run by Johns Hopkins Bloomberg School of Public Health at 1 site in Uganda.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Intimate partner violence (IPV) is a precursor to and consequence of HIV infection. Few interventions combining HIV and IPV prevention have been evaluated and none has significantly decreased both outcomes. A cluster-randomized trial was conducted in Rakai, Uganda. Read more about this study

Who is it for?
Ages 15 to 49 yearsHealthy volunteers can take part
What is being tested?
The SHARE Project
Could I receive a placebo?
No, everyone receives an active treatment
How many people
11,451 participants
Where
1 siteUganda
Study dates
Feb 2005to Nov 2009
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 15 to 49 years
  • All sexes
  • Healthy volunteers accepted
  • Child, Adult

Who may be able to join

  • Between the ages of 15-49 years;
  • Consent to participation;
  • Resident of at least 6 months in study community;
  • Enrollment into RCCS at baseline (2005-06);
  • Report of sexual activity or being in a partnership in the year prior to the baseline interview;
  • Provision of follow-up information on variables of interest.
  • For HIV incidence, only participants with initial HIV-negative serostatus at their baseline visit were included in the analyses.

Who cannot join

  • Younger than 15 years and older than 49 years;
  • Did not consent to participation;
  • Non-resident in study community;
  • Not enrolled in RCCS between 2005-06;
  • Not yet sexually active or not sexually active during year prior to baseline;
  • Incomplete follow up information on variables of interest;
  • HIV positive at baseline

Trial locations and contacts

1 site in 1 country.

Uganda1 site
  • Rakai Health Sciences Program

    Kalisizo, Rakai

Other trials in Uganda

About this study

Official title: A Cluster Randomized Trial of the Impact of an Intimate Partner Violence and HIV Prevention Intervention on Emotional, Physical and Sexual Abuse, Sexual Risk Behaviors and HIV Incidence in Rakai, Uganda

Intimate partner violence (IPV) is a precursor to and consequence of HIV infection. Few interventions combining HIV and IPV prevention have been evaluated and none has significantly decreased both outcomes.

A cluster-randomized trial was conducted in Rakai, Uganda. Four intervention arm clusters (N=5,339) received an IPV prevention intervention (the Safe Homes and Respect for Everyone (SHARE) Project), enhanced HIV testing and treatment and routine HIV services provided by Rakai Health Sciences Program (RHSP). Seven control arm clusters (N=6,112) received standard of care HIV services alone.

Read more

Baseline and two follow-up visits were conducted via the Rakai Community Cohort Study between 2005 and 2009. Primary outcomes were past year emotional, physical and sexual IPV and HIV incidence. Secondary outcomes included past year intimate partner rape/forced sex, number of total and extra-marital sex partners, alcohol use surrounding sex, condom use, discussion about condom use, partner's disclosure of HIV status and respondent's disclosure of HIV status. Analysis was by intention-to-treat. Modified Poisson regression was used to estimate prevalence risk ratios (PRR) to detect the impact of the intervention on IPV and secondary outcomes. Poisson regression was used to estimate incidence rate ratios (IRR) of HIV acquisition per 100 person years (py).

Our study had three research aims and related hypotheses.

Aim 1 was to assess the impact of SHARE + RHSP community services on report of victimization from and perpetration of physical and/or sexual IPV in the past 12 months, compared to the impact of RHSP community services alone.

Hypothesis 1(a): SHARE intervention will reduce women's reports of IPV victimization in intervention vs. control arms.

Hypothesis 1(b): SHARE intervention will reduce men's reports of IPV perpetration in intervention vs. control arms.

Aim 2 was to assess the impact of SHARE + RHSP services on report of sexual risk behaviors among men and women compared to the impact of RHSP community services alone.

Hypothesis 2(a): SHARE intervention will reduce selected sexual risk behaviors in the intervention vs. control arms.

Aim 3 was to assess the impact of SHARE + RHSP services on HIV incidence compared to the impact of RHSP community services alone.

Hypothesis 3(a): Incidence of HIV will be lower in the intervention vs. control arms.

Read the detailed description

Research Team: Rakai Health Sciences Program Data collection for the proposed dissertation analysis was done by the research teams and investigators from Rakai Health Sciences Program (RHSP) which was established in 1988 with a focus on HIV/AIDS research, including evaluation of health education and condom promotion. Over time activities have increased in nature and volume and expanded to include laboratory and clinical research, randomized trials of new prevention strategies, health professional training, expanded community services including HIV voluntary testing and counseling, provision of HIV antiretroviral therapy (ART), general and HIV-related medical care, prevention of mother-to-child transmission of HIV (PMTCT), and family planning services. In 2002, the Rakai Program became an International Center for Excellence in Research (ICER), sponsored by the National Institute of Allergy and Infectious Diseases (NIAID). The core of the RHSP is the 18-year community-based longitudinal Rakai Community Cohort Study (RCCS), within which the RHSP has implemented multiple interdisciplinary studies. Over 150 peer-reviewed papers have been generated from the RCCS and its nested studies.

Data Source: Rakai Community Cohort Study All data for the proposed analysis were derived from the Rakai Community Cohort Study (RCCS) which conducts survey interviews every 12-18 months with all consenting people aged 15-49 in ~5,000 households in 47-50 communities throughout Rakai. These 47-50 communities represent 7% of the 720 communities situated in Rakai District. The RCCS includes participants residing in trading centers and agrarian villages, representative of rural southwestern Uganda. Each RCCS participant receives a unique, life-long study identification number used to link data over time and between RHSP studies. RCCS written informed consent forms cover study participation, sample archiving for future assays including genetic testing, linkage of RCCS data to other RHSP databases, and permission to re-contact participants for other studies.

Trial Design The SHARE intervention trial used a cluster randomized controlled design where study regions rather than individuals were selected to receive (or not receive) exposure to the intervention, with all consenting adults in the community being offered treatment (intervention). The community-based approach was selected because offering a partner violence prevention intervention to individuals without involving their intimate partners would not achieve holistic results. IPV involves both members of the couple and its prevention must likewise target both.

The SHARE intervention trial was done via the Rakai Community Cohort Study (RCCS) which operates in ~50 communities which were aggregated into 11 study regions (categorized as rural or semi-urban) for a prior trial of sexually transmitted disease control and HIV transmission prevention conducted between 1994 and 1999. A previous FP outreach trial (1999 and 2002) had randomized these communities,35 and the SHARE study built on this prior randomization whereby the SHARE intervention was implemented in 4 regions (Buyamba, Kabira, Kalisizo, Katana) of the total 11 RCCS research areas. . For the current trial, four of the six FP intervention clusters were randomly assigned to the IPV intervention arm.

The process used to select regions for exposure to the SHARE trial built on a previous cluster randomized trial (CRT) that was conducted between 1999 and 2002 to assess the impact of family planning outreach via social marketing in Rakai. For the family planning CRT, 5 clusters were randomly selected to receive standard family planning services while 6 clusters were assigned to the intervention arm and received additional family planning information, counseling, and contraceptive methods from government service providers and community-based volunteer agents using social marketing and other strategies. Condom use was promoted in both control and intervention areas. Findings indicated family planning outreach via social marketing can significantly increase hormonal contraceptive use and decrease pregnancy rates. No differentials were found, however, in condom use between study arms.

In 2005, 4 of the 6 family planning intervention clusters were randomly assigned to the intervention arm of the SHARE trial. The remaining 2 family planning intervention clusters, as well as all 5 family planning control clusters were assigned to the control arm of the SHARE intervention trial, making a total of 7 control regions in the SHARE trial. The decision to allocate only 4 communities to intervention was based on budgetary constraints which precluded a larger number of intervention areas.

RCCS rounds and intervention trial implementation

Data from 2 rounds of the RCCS, R1 and R2, will be analyzed for the proposed study:

R1 = baseline, pre-intervention (Feb 2005-Jun 2006) R2 = post-intervention follow-up (Aug 2006-Apr 2008) R3 = post-intervention follow-up (Jun 2008-Nov 2009)

Baseline interviews were conducted in all 4 intervention and 7 control regions via RCCS between February 2005 and June 2006. SHARE was rolled out in the 4 intervention regions between August 2005 and November 2006. SHARE activities were introduced in each intervention region only after all baseline data collection had been completed for the entire study area. Because regions are surveyed via RCCS in the same order during each annual/semi-annual round, we estimate that each intervention community had approximately the same length of exposure to SHARE before each point of follow-up.

Independent/Dependent Variables and Confounders

Independent (exposure) variables

There are 2 independent variables for the proposed study: RCCS round and arm of the trial

  1. RCCS round:
  2. Pre-intervention baseline (R1)
  3. Post-intervention follow-up time 2 (R2)
  4. Post-intervention follow-up time 2 (R3)
  5. Arm of trial
  6. Intervention arm
  7. Control arm Dependent (outcome) variables The primary dependent variable is past year experience of IPV (victimization among women, perpetration among men). Secondary outcome variables include number of non-marital sexual partners, condom use in the past 6 months, alcohol use at last sex and HIV incidence. All dependent variables will be determined at baseline, post-intervention time 1 and time 2. Confounders Potential confounding variables will be assessed at baseline to determine comparability between arms. The association between potential confounders and outcomes of interest will be assessed by univariate analyses, and potential covariates will include; age, sex (gender), education, marital status, religion, pregnancy-status, reproductive/fertility preferences, HIV-status, use of VCT, household socio-economic status. We will also assess the associations between sexual behaviors and IPV/HIV acquisition. Intention to Treat An intention to treat approach will be used in which all participants with evaluable data for each outcome measure will be included in the analysis by randomization arm. Retention rates will be estimated by arm. Analysis Plans The proposed statistical analysis will follow four key steps. Step 1 - Establish baseline comparability First, the characteristics of study participants will be assessed at pre-intervention (baseline) in both the control and intervention regions. Comparability of the two arms at baseline is important for designing final statistical analysis models capable of adjusting for any differences and assessing the impact of the intervention with minimal or no confounding. Pre-intervention data on outcome variables, socio-demographic and covariates will be analyzed, using descriptive statistics and graphics to display in the control and intervention communities. Exploratory analysis will include frequencies for dichotomous and categorical variables, using X2 and Fisher's exact tests for differences in proportions. Continuous variables will be assessed by means and medians using t-tests and Wilcoxon rank test. Step 2 - Investigate associations between intervention exposure and primary/secondary outcomes The second analytic step will be to investigate the associations between intervention exposure and the primary and secondary outcomes (past year IPV, condom use, alcohol use with sex, number of non-marital partners and HIV incidence) using univariate regression analyses. Covariates (characteristics or behaviors) found to be correlated with outcomes of interest in the univariate models at the p<0.15 significance levels will be included in subsequent multivariate models. Step 3 - Construct adjusted multivariate models Adjusted multivariate regression models will be constructed for outcomes found to be significantly predicted by intervention exposure. Details are provided in the subsequent section on data modeling and power calculations for the 3 aims of the proposed dissertation research. Proposed Data Modeling and Power Calculations by Research Aim AIM 1 - Intimate Partner Violence Outcome To assess the impact of SHARE + RHSP community services on report of victimization from and perpetration of physical and/or sexual IPV in the past 12 months, compared to the impact of RHSP community services alone. Statistical Modeling for Aim 1 The measures of past year experience of IPV will be analyzed separately for physical and sexual IPV and both will be modeled categorically. Three categories of physical violence will be used: (1) None (referent); (2) Moderate physical IPV; (3) Severe physical IPV. Two categories of sexual violence will be used: (1) None (referent); (1) Any sexual violence. Participants who report any experience (victimization or perpetration) of physical or sexual IPV in the past 12 month will be counted as having experienced the outcome. The proportion of each type of IPV will be tabulated by follow-up visit, and unadjusted differences between trial arms will be assessed using χ2 and Fisher's exact tests. The proportion of each type of IPV will be calculated separately for men (perpetration) and women (victimization). Behavior changes will be evaluated from baseline to follow-up (i.e. the second post-trial follow-up) by which time individuals in intervention regions had been exposed to the SHARE intervention for more than one year. Linear regression models will be fitted to estimate the marginal distributions of repeated outcomes to compare the within-individual behavior changes in relation to exposure or non-exposure to the intervention. The following equation will be used where Yit denotes the absence/presence of each type of IPV for every unit i at each time t. Yit = β0 + β1G + β2T + β3(G×T) + β4X1... + βkXk +εit Covariates included in the multivariate models will be characteristics or behaviors found to be correlated with IPV outcomes in univariate analyses at p<0.15. Models will also adjust for any statistically significant lack of comparability between the trial arms at baseline. Statistical inference for individual covariates will be based on the Wald statistic, and model fit assessed by the log likelihood ratio test (LRT). The difference between follow-up and baseline measures of IPV will be calculated separately for intervention and control regions and the difference in changes will be assessed under the null hypothesis that there is no DiD: (IPV-IntFup - IPV-IntB) = (IPV-CF - IPV-Cb). The statistical significance of the interaction coefficient, β3, will be obtained using the Wald statistic, and model fit assessed by the log likelihood ratio test (LRT). All hypothesis tests will be two sided with significance levels of 0.05. Behavioral variables found to have changed significantly during the post-trial follow-up will be further analyzed through repeated fitting of the linear model analyses stratifying by age group, type of community (rural vs. urban), and other important variables to investigate if behavior changes are associated with specific characteristics of individuals or populations. Power Calculations for Aim 1 Data on the impact of SHARE + RHSP community services on past year IPV will be analyzed to present (1) the percent change (reduction or increase) or lack thereof of reports of the IPV outcome in both groups (intervention and control) from baseline to follow-up; (2) the difference in the percent change of the IPV outcome between intervention and control groups. For Aim 1, power estimates were calculated to assess the study's power to measure percent change (reduction or increase) of IPV from baseline to follow-up, assuming there will be comparability in the percentages reported pre-intervention in both arms. Thus, study power estimates were calculated for the primary outcome of past year IPV based on (1) the set sample size for each round of data collection, (2) baseline prevalence of each type (physical and sexual) of IPV (3) assumptions regarding the expected magnitude of decline in each type of IPV that might result from the SHARE intervention combined with RHSP HIV prevention activities. Two sets of power calculations were used for physical IPV (moderate and severe combined) and sexual IPV. The sample size is fixed as per Table 3. STATA 1059 was used to estimate power to detect a minimum percent reduction, assuming a two-sided α = 0.05 with an approximate intervention population of 3,500 and an approximate control population of 11,100 at both time points. Baseline prevalence of different IPV types are based on RCCS data suggesting 20% of women experienced physical IPV and 14.5% experienced sexual IPV during the year before the survey. It is thus estimated that the study has 80% power to detect as little as a 7% reduction in the proportion of individuals reporting physical IPV and as little as a 16% reduction in the proportion of individuals reporting sexual IPV in both arms between baseline and follow-up. AIM 2 - Sexual Risk Behavior Outcomes To assess the impact of SHARE + RHSP community services on report of sexual risk behaviors, including non-marital partnerships in the past year, condom use over the past 6 months and use of alcohol before sex among men and women compared to the impact of RHSP community services alone. Statistical Modeling for Aim 2 The three measures of past year sexual risk behaviors will be analyzed separately for non-marital partnerships, condom use in the past 6 months, and alcohol use at last sex. All outcomes will be modeled categorically. Non-marital partners Number of non-marital sex partners in the past year will be modeled as a categorical outcome: (1) no non-marital partner (referent); (2) one non-marital partner; (3) two or more non-marital partners. Condom use in the past 6 months Condom in the past 6 months will be modeled categorically as: (1) no condom use (referent); (2) inconsistent use; and (3) consistent use. Alcohol use at last sex Alcohol use at last sex will be modeled categorically as: (1) no alcohol use at last sex (referent); (2) any alcohol use at last sex. The proportion of each type of sexual risk behavior reported will be tabulated by follow-up visit, and unadjusted differences between trial arms will be assessed using χ2 and Fisher's exact tests. The proportion of each type of IPV will be calculated separately for men and women and behavior changes will be evaluated from baseline to follow-up. Linear regression models will be fitted to estimate the marginal distributions of repeated outcomes67 to compare the within-individual behavior changes in relation to exposure or non-exposure to the intervention. The following equation will be used where Yit denotes the absence/presence of each type of sexual risk behavior for every unit i at each time t: Yit = β0 + β1G + β2T + β3(G×T) + β4X1... + βkXk +εit The remainder of the description of statistical methods for Aim 2 is identical to that of Aim 1. Power Calculations for Aim 2 Estimates were calculated to assess the study's power to measure percent change (reduction or increase) of each sexual risk behavior from baseline to follow-up, assuming comparability at baseline in in both arms. Again, study power estimates were calculated were based on (1) the set sample size for each round of data collection and (2) baseline prevalence, derived from Rakai data, of each type of sexual risk behavior. Three sets of power estimates were calculated. Non-marital partners: Rakai data indicated approximately 61% of men and 10% of women had more than one non-marital sex partner in the past year,49 the proposed analysis has 80% power to detect as small as a 3% reduction in men and an 11% reduction in women from time one to time two in each arm. Condom use: Data on condom use in the last six months was not available. But it is estimated that 6.5% of men and 3% of women consistently used condom use in the past year. 49 Based on these findings, it is estimated that the proposed analysis has the power to detects as small as 15% increase in consistent condom use among women and as small as a 23% increase in consistent condom use among men. Alcohol use at last sex: Previous Rakai findings suggest that 75.5% of men and 37% of women drink alcohol before sex. Based on these findings, it is estimated that the proposed analysis has the power to detect as small as 2% and 5% decrease in alcohol use with sex among men and women, respectively. AIM 3 - HIV Incidence Outcome To assess the impact of SHARE + RHSP community services on HIV incidence. Statistical Modeling for Aim 3 For Aim 3, data from all 3 rounds of RCCS will be analyzed. Person years (PY) of exposure will be cumulated from baseline to the last negative HIV result if the person remained negative, or to the midpoint of the interval between the last negative tests and first positive tests for seroconverters. HIV incidence will be estimated per 100 PY. The primary analysis will be intention-to-treat, using a log link and Poisson distribution to estimate the incidence rate ratios (IRR) of HIV acquisition. Random effects models will be used to account for intra-region correlation. All models will be adjusted by study region. In univariate analyses we will assess covariates associated with HIV acquisition at p<0.15 to determine potential confounders for inclusion in multivariate models. Models will also adjust for any statistically significant baseline differences between randomization arms. Potential covariates include terms for sex, age, sexual risk behaviors, and community baseline prevalence of HIV. Homogeneity of the treatment effect in men and women will be assessed by testing for a sex by treatment interaction. Results of these models will be used to estimate the number of HIV infections prevented by the intervention over a ~4.5 period per 100 participants. Power Calculations for Aim 3 Assuming 75% annual retention and two follow up intervals post-intervention, we estimate we will have ~4,753 PY of exposure in the intervention group and ~16,969 PY of exposure in the control group. The power to detect minimal IRRs with this person time was estimated using STATA 1059 assuming a two sided α =0.05 and an HIV incidence estimate of 1.5/100 PY among women and 1.4/100 PY among men. The study has 80% power to detect a 36% lower HIV incidence in intervention compared to control communities over time of follow-up. ETHICAL CONSIDERATIONS Several steps were taken by the RHSP to ensure the safety and confidentiality of all research participants. Because this is secondary data analysis, the main risk is breach of confidentiality if participant records, interviews or lab results are revealed to third parties. Informed consent documents are retained in locked filing cabinets and store rooms, accessible only to senior investigators or designated staff. All questionnaires and samples are identified by pre-printed study ID numbers, and names are removed. All questionnaires are stored in secure, locked facilities in the field station in Kalisizo and permanent stores in Entebbe. Only designated staff members have access to these records. All computerized data bases contain study ID numbers and the lists linking study numbers to names is kept separately in a password protected computer accessible only to senior data managers. Files of lab results are maintained in a separate safe computer file, with study ID numbers, and contain no personal identifiers. The RCCS interviews for this study were conducted in the respondents' homes or at a central location (referred to as a "hub"). Interviews were done in complete privacy in the language of Luganda by experienced same-sex interviewers using structured questionnaires. Recognizing that research on IPV raises important ethical and methodological challenges beyond those posed by general population health research, RHSP investigators followed recommendations developed by the WHO regarding the safe and ethical conduct of domestic violence research. IRB approval for the original study data was granted under two studies "Rakai Community Cohort Study" and "Assessing the impact of community-based intervention designed to reduce levels physical and sexual domestic violence in Rakai District, Uganda." The "Rakai Community Cohort Study" received IRB approval from WIRB (WIRB PRO#20031318) and the study "Assessing the impact of community-based intervention designed to reduce levels physical and sexual domestic violence in Rakai District, Uganda" received approval from the IRB of the World Health Organization (WHO.A55085). Both studies also received ethical approval from the Uganda Virus Research Institute's Science Ethics Committee and the Ugandan National Council of Science and Technology. Ethical approval for the proposed secondary analysis was received by WIRB as a sub study to the ongoing Rakai Community Cohort study (WIRB PRO#20031318). All enrollment and data collection has ended.
Being tested
The SHARE Project
Keywords
HIV, Intimate partner violence, Community based prevention intervention, Uganda, Cluster randomized trial
Medical subject headings
Risk Reduction Behavior

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • The SHARE ProjectBehavioural

    SHARE aimed to reduce IPV and used methodologies from two proven successful violence prevention frameworks: Stepping Stones (Welbourn, 1995) and the Resource Guide for Mobilizing Communities to Prevent Domestic Violence (Michau \& Naker, 2003). SHARE promoted a process of social change based on the Transtheoretical Model's Stages of Change Theory (Prochaska \& DiClemente, 1983; Prochaska \& Velicer, 1997) which posits that although people realize they need to make changes in their life, they do it in stages instead of one major life change. There are five main stages of change: (1) pre-contemplation, (2) contemplation, (3) preparation for action, (4) action and (5) maintenance.

    We hypothesized that repeated exposure to the ideas included in SHARE would encourage men and women to begin a process of change that results in preventive behavior.

Study groups in NCT02050763
Study groupRoleWhat they receive
Intervention armExperimentalIntervention arm clusters (n=4) received an IPV prevention intervention (the Safe Homes and Respect for Everyone (SHARE) Project), enhanced HIV testing and treatment and routine HIV services.
Receives: Behavioral: The SHARE Project
Control armNo interventionControl arm clusters (n=7) received standard of care HIV services alone.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Intimate partner violence

    Physical violence was measured by asking female participants, "In the past 12 months has your current partner done any of the following to you: Pushed, pulled, slapped, or held you down? Punched you with fist or with something that could hurt you? Kicked you or dragged you? Tried to strangle you or burn you? Threatened you with a knife, gun or other type of weapon? Attacked you with knife, gun, or other weapon?" (Yes/No)

    Sexual IPV was measured by asking female participants, "In the past 12 months has your current partner done any of the following to you: Used verbal threats to force you to have sex when you did not want to? Physically forced you to have sex when you did not want to? Forced you to perform other sexual acts when you did not want to?" (Yes/No)

    Emotional intimate partner violence was measured by asking female participants, "In the past 12 months, has your current partner verbally abused or shouted at you?" (Yes/No).

    Measured: One year

Secondary outcomes (10)
  1. HIV incidence

    HIV incidence was determined from venous blood samples, using two enzyme immunoassay (EIA), with Western blot (WB) and/or polymerase chain (PCR) confirmation of discordant EIA results and for all seroconversions.

    Measured: One year

  2. Non-marital partnerships

    Non-marital partnerships were assessed by asking respondents, "Do you currently have a relationship with someone to whom you are not officially married or in a consensual union?"

    Measured: One year

  3. Condom use

    Past year condom use was measured through two questions: "During the past 12 months have you/partner used condoms?" and those who responded "yes" were asked about if they used condoms consistently, sometimes (inconsistently) or always.

    Measured: One year

  4. Alcohol use

    To assess alcohol use, participants were asked, "Did you drink alcohol before your last sex with this partner?" (Yes/No)

    Measured: One year

  5. Circumcision status

    Circumcision status of male participants and male partners of female participants was assessed by asking men "Are you circumcised?" and women "Is your partner circumcised?"

    Measured: One year

  6. Intimate partner rape

    "In the past 12 months have any of your sexual partners physically forced you to have sex when you did not want to?" [YES/NO] Victimization was measured among women and perpetration measured among men.

    Measured: One year

  7. Multiple (more than 1) sexual partners

    Multiple (more than 1) sexual partners was measured by asking, "How many different sexual partners have you had in the last 12 months, including married or consensual partners, and anyone already mentioned?" [One/two or more]

    Measured: One year

  8. Discussion about condom use

    Discussion about condom use was measured by asking, "Have you discussed condom use with this partner?" [NO/YES]

    Measured: One year

  9. Partner's disclosure of HIV status

    Partner's disclosure of HIV status was measured by asking, "In the last 12 months has this partner informed you of his/her HIV sero-status?" [No or never got tested/results / Yes or received couple counseling]

    Measured: One year

  10. Self-disclosure of HIV status

    Self-disclosure of HIV status was measured by asking, "In the last 12 months have you informed this partner of your HIV serostatus?" [No or never got tested/results / Yes or received couple counseling]

    Measured: One year

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted31 Jan 2014 (estimated)
  2. Study startFeb 2005
  3. Primary completionNov 2009
  4. Study completionNov 2009

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Single group
Masking
None (open label)
Enrolment
11,451 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02050763
Sponsor's protocol ID
1F31MH095649-01A1
Other IDs
WIRB Protocol # 20031318
Acronym
SHARE
Status last verified
Jan 2014
First submitted
28 Jan 2014
Last updated
15 Oct 2014
Results posted
No
Data monitoring committee
Yes

Publications

  • Prochaska JO, Velicer WF. The transtheoretical model of health behavior change. Am J Health Promot. 1997 Sep-Oct;12(1):38-48. doi: 10.4278/0890-1171-12.1.38.

    PubMed 10170434
  • Prochaska JO, DiClemente CC. Stages and processes of self-change of smoking: toward an integrative model of change. J Consult Clin Psychol. 1983 Jun;51(3):390-5. doi: 10.1037//0022-006x.51.3.390. No abstract available.

    PubMed 6863699
  • Wagman JA, Namatovu F, Nalugoda F, Kiwanuka D, Nakigozi G, Gray R, Wawer MJ, Serwadda D. A public health approach to intimate partner violence prevention in Uganda: the SHARE Project. Violence Against Women. 2012 Dec;18(12):1390-412. doi: 10.1177/1077801212474874.

    PubMed 23419276
  • Wagman JA, Gray RH, Campbell JC, Thoma M, Ndyanabo A, Ssekasanvu J, Nalugoda F, Kagaayi J, Nakigozi G, Serwadda D, Brahmbhatt H. Effectiveness of an integrated intimate partner violence and HIV prevention intervention in Rakai, Uganda: analysis of an intervention in an existing cluster randomised cohort. Lancet Glob Health. 2015 Jan;3(1):e23-33. doi: 10.1016/S2214-109X(14)70344-4. Epub 2014 Nov 28.

    PubMed 25539966

Questions about this trial

What is this clinical trial studying?

A study testing The SHARE Project in people with HIV and Physical Abuse of Adult (If Focus of Attention is on Victim), run by Johns Hopkins Bloomberg School of Public Health at 1 site in Uganda.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 7 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 15 Oct 2014. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Uganda. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Intimate partner violence (time frame: One year). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02050763, which also lists 4 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Oct 2014.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in